With data analytics and artificial intelligence (AI), an Indian pharmaceutical company
Purple Biotech Ltd has announced new biomarker data for oncology drug CM24, a first-in-class anti-CEACAM1 monoclonal antibody. The findings were presented in a scientific poster titled "Phase 1 Study of CM24 in Combination with Nivolumab in...
Rainbow Children's Medicare Limited (RCML), India's foremost pediatric multi-specialty and prenatal care hospital chain, has signed an MoU (memorandum of understanding) with the Government of Tanzania to establish comprehensive inter...
Aktivolabs has declared HIPAA compliance and the opening of its US operations. The firm is on a global mission to avoid chronic illnesses. Enterprises and governments may use the real-time digital health platform to create scalable, evidence-based...
Paradigm has announced a partnership with Bristol Myers Squibb to develop a new end-to-end clinical trial operating model that spans design, recruitment, and data collection. Beginning with oncology and eventually expanding to other therapeutic...
Novartis announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) intravenous (IV) formulation for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non...
Zhifei, China's largest vaccines producer, will pay British drugmaker GSK 2.5 billion pounds ($3.05 billion pounds) for exclusive distribution rights to GSK's shingles vaccine in the world's No.2 pharmaceuticals market. The agreement is part of a...
The FDA has approved Biomea's IND application to study BMF-219 in adults with type 1 diabetes, according to Biomea Fusion, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to...
Bristol Myers Squibb, a US pharmaceutical corporation, announced a $4.8 billion deal to purchase cancer drugmaker Mirati Therapeutics. Bristol Myers Squibb will pay $58 per share in cash "for a total equity value of $4.8 billion," according to the...
The US Food and Drug Administration (FDA) has approved EntroGen's CRCdx RAS Mutation Detection Kit as a companion diagnostic for Vectibix (panitumumab), a colorectal cancer targeted therapy. This historic premarket approval (PMA) represents a...
, CDSCO.jpg)
.jpg)